State Department info up until not long ago, maybe a bit more than 20 years, stated that to become president one had to be born on US soil to two US citizen parents. Parents could be naturalized of course, but before child is born.
*****************************************************************************************
And that is what I was taught in Citizenship class in 9th grade.
During the Obama campaign, I examined the state department documents/instructions for citizenship.
It did make a distinction between born a citizen and natural born citizen. And indicated that it was not certain that a person born to citizen parents overseas could meet the definition of natural born citizen for the purposes of Article II determination of eligibility for president.
It stated that there had never been a case to definitively establish it one way or the other. Always pushing to dilute the requirements...or so it seems. Grrr.
On the natural born citizenship research threads, one president whose name I can’t remember, was not a NBC because his father was Irish and had not naturalized when the son was born. I THINK this president was a VP who assumed office. Sorry I am so poor at remembering the details. Anyway, there was suspicion that his father had not been a citizen as the time he was born, so he burned documents to hide the facts.
So it was actually accepted for most of our country’s history, as you noted, that a natural born citizen means born on US soil with two citizen parents.
publication of Dr. Zelenko data (NY state) using HCQ, Zn, Zpack
https://twitter.com/zev_dr/status/1279010904911249409
https://www.preprints.org/manuscript/202007.0025/v1 download pdf at link ; note not double-blind/randomized
Objective: To describe outcomes of patients with coronavirus disease 2019 (COVID-19) in the outpatient setting after early treatment with zinc, low dose hydroxychloroquine, and azithromycin (the triple therapy) dependent on risk stratification. Design: Retrospective case series study. Setting: General practice. Participants: 141 COVID-19 patients with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in the year 2020. Main Outcome Measures: Risk-stratified treatment decision, rate of hospitalization and all-cause death. Results: Of 335 positively PCR-tested COVID-19 patients, 127 were treated with the triple therapy. 104 of 127 met the defined risk stratification criteria and were included in the analysis. In addition, 37 treated and eligible patients who were confirmed by IgG tests were included in the treatment group (total N=141). 208 of the 335 patients did not meet the risk stratification criteria and were not treated. After 4 days (median, IQR 3-6, available for N=66/141) of onset of symptoms, 141 patients (median age 58 years, IQR 40-60; 73% male) got a prescription for the triple therapy for 5 days. Independent public reference data from 377 confirmed COVID-19 patients of the same community were used as untreated control. 4 of 141 treated patients (2.8%) were hospitalized, which was significantly less (p<0.001) compared with 58 of 377 untreated patients (15.4%) (odds ratio 0.16, 95% CI 0.06-0.5). Therefore, the odds of hospitalization of treated patients were 84% less than in the untreated group. One patient (0.7%) died in the treatment group versus 13 patients (3.5%) in the untreated group (odds ratio 0.2, 95% CI 0.03-1.5; p=0.16). There were no cardiac side effects. Conclusions: Risk stratification-based treatment of COVID-19 outpatients as early as possible after symptom onset with the used triple therapy, including the combination of zinc with low dose hydroxychloroquine, was associated with significantly less hospitalizations and 5 times less all-cause deaths.